Stock Taper
SCREENER COMPARE ANY 2 STOCKS
INDV
INDIVIOR PHARMACEUTICALS INC
NASDAQ
$34.87
▼ DOWN 1.22% (-0.43)

KEY STATISTICS

Market Cap$4.35 B
52w High$42.81
52w Low$22.22
Dividend Yield4.04%
FrequencySemi-Annual
P/E9.55
Volume2.20M
Shares Out.124.77M

COMPANY

LEADERSHIP

Joseph J. Ciaffoni
CHIEF EXECUTIVE
Joseph J. Ciaffoni

COMPENSATION 2026

Salary$902,261
Stock Awards$162,518
Incentive Plan Pay$2,054,522
All Other Comp.$66,290
Total$3,185,591

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 29, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
833

PRICE TARGET

Target High$53.00
Target Low$43.00
Target Median$48.00
Target Consensus$48.00

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$329.35M
OCT
29
THU

SPLIT RECORD

DATETYPERATIO
2022-10-17Reverse1:5
2022-10-10Reverse1:5

PRICE

$34.87 ▼ DOWN 1.22% (−$0.43)
OVERLAYS
$34.50$34.80$35.10$35.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM34.87

About Indivior Pharmaceuticals Inc

https://www.indivior.com ↗

Indivior Pharmaceuticals Inc. develops, manufactures, and sells buprenorphine-based drugs for opioid dependence treatment, including Suboxone and Subutex, operating globally from North Chesterfield, VA.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT INDIVIOR PHARMACEUTICALS INC IS KNOWN FOR

SUBLOCADE® (buprenorphine extended-release)
SUBLOCADE® (buprenorphine extended-release)

SUBLOCADE® is Indivior's once-monthly injectable for moderate to severe opioid use disorder, driving significant revenue growth and benefiting from recent FDA label updates to facilitate patient initiation.

COMPETITORS

COMPETITOR
ALKS COMPARE
AMRX COMPARE
BHC COMPARE
COLL COMPARE
TEVA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Reportable Segment$314M $357M ▲$317M ▼$343M ▲

Revenue by Geography

MapREGIONFY2023FY2024
UNITED STATES$912M $3M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
199
LISTED HERE
26
RANKED BY POSITION SIZE
IJR.AX
0.24% · 7.4M
VTS.AX
0.01% · 3.9M
XSMO
1.97% · 1.7M
SPSM
0.24% · 1.1M
SCHA
0.09% · 579.9K
DFAS
0.08% · 349.9K
PSC
0.38% · 299.7K
XRS2.DE
0.13% · 109.4K
FSMD
0.13% · 95.7K
FSCC
1.05% · 94.4K
RSSL
0.13% · 57.3K
GSSC
0.17% · 53.4K
SIXS
1.15% · 47.1K
FSML
1.01% · 43.0K
JHSC
0.17% · 34.2K
JPSE
0.20% · 33.7K
EZM
0.12% · 32.2K
GVLU
0.33% · 24.2K
TILT
0.03% · 21.3K
SMIZ
0.26% · 20.6K
AFSM
0.43% · 16.0K
ROSC
1.00% · 15.3K
MEDI
1.05% · 13.0K
RTWP.L
0.19% · 11.9K
ZSML.TO
0.24% · 11.8K
SMDX
0.28% · 10.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
406
TOP 12 OF 406 · RANKED BY POSITION SIZE
Oaktree Capital Management LP
257.8M sh · $10.69M
Blackrock, Inc.
18.7M sh · $767.65M
Two Seas Capital LP
10.5M sh · $253.26M
Deerfield Management Company, L.P. (Series C)
7.0M sh · $168.45M
Goldman Sachs Group Inc
6.6M sh · $158.57M
Madison Avenue Partners, LP
6.5M sh · $155.84M
Fuller & Thaler Asset Management, Inc.
6.4M sh · $228.61M
Morgan Stanley
5.6M sh · $135.58M
Vanguard Group Inc
5.5M sh · $196.4M
State Street Corp
5.0M sh · $204.82M
Millennium Management LLC
4.6M sh · $140.07M
Newtyn Management, LLC
4.2M sh · $101.26M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF ACCOUNTING OFFICER
Anderson Woodrow D
Purchase · 1.5K shares
2026-08-27
★
OFFICER: CHIEF ACCOUNTING OFFICER
Anderson Woodrow D
Purchase · 1.5K shares
2026-08-05
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Heidbreder Christian
Sale · 18.6K shares
2026-07-10
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Ciaffoni Joseph
Sale · 612.5K shares
2026-06-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
BUY 1
3 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT HC Wainwright & Co. BUY Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
PRAX$344.75COMPARE
CRNX$84.84COMPARE
HNGE$87.35COMPARE
LNTH$100.77COMPARE
AMRX$17.54COMPARE
ACAD$29.11COMPARE
VKTX$32.16COMPARE
OPCH$23.90COMPARE